Ultrasound contrast developer Point Biomedical said that the Food and Drug Administration has accepted its new drug application (NDA) for review of the firm's Cardiosphere myocardial perfusion agent.
The San Carlos, CA-based firm is seeking clearance to market the agent for the detection and localization of obstructive coronary artery disease.
By AuntMinnie.com staff writers
February 28, 2006
Related Reading
Point Biomedical scores financing, August 19, 2004
Copyright © 2006 AuntMinnie.com